On January 9, 2015, Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, announced a partnership for the manufacture of RNA medicines.

Under the terms of the agreement, Precision’s proprietary NanoAssemblr™ platform will be used to manufacture GMP batches to support clinical studies and commercial development for RNA medicines developed using Arcturus’ proprietary LUNAR™ RNA Therapeutics platform.

Paul Armitage of Gowlings advised Precision NanoSystems with respect to the negotiation of this partnership.